You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Johnson and Johnson
Boehringer Ingelheim
Medtronic
Dow

Last Updated: February 23, 2024

CLINICAL TRIALS PROFILE FOR TRIZIVIR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Trizivir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004981 ↗ Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir) Unknown status Glaxo Wellcome Phase 3 1969-12-31 The purpose of this study is to look at the safety and effectiveness of a pill called Trizivir that is a combination of three anti-HIV drugs (zidovudine, lamivudine, and abacavir). Zidovudine and lamivudine are often given combined in one pill (Combivir). In this study, Trizivir will be compared to Combivir plus abacavir.
NCT00011895 ↗ Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status GlaxoSmithKline Phase 4 2001-02-01 The purpose of this study is to determine the effect of treatment with Trizivir (TZV) plus efavirenz (EFV) or TZV alone on viral load (level of HIV in the blood).
NCT00038506 ↗ Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure Completed ViiV Healthcare Phase 4 2002-03-01 This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen.
NCT00043888 ↗ Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR Completed GlaxoSmithKline Phase 3 2002-01-01 Antiretroviral Therapy (ART) naive subjects will be enrolled in this clinical research study to test the safety and tolerability of fosamprenavir with or without ritonavir in combination TRIZIVIR and COMBIVIR. Subjects will receive 24 weeks of therapy.
NCT00082394 ↗ A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV Completed GlaxoSmithKline Phase 4 2004-04-26 The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily. Over the course of 48 weeks, various parameters that measure safety, tolerability and efficacy of the investigational drugs were measured and compared.
NCT00084149 ↗ Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2004-02-01 Cyclosporine A (CsA) is a common long-term treatment used to inhibit the immune response in transplant patients who receive donor organs. CsA may also help people with HIV. The purpose of this study is to determine the safety of and immune response to CsA when given with abacavir sulfate (ABC), lamivudine (3TC), and zidovudine (AZT), (ABC/3TC/AZT) and lopinavir/ritonavir (LPV/r) to HIV infected adults in the early stages of infection. Study hypothesis: The combination of CsA and LPV/r given to acutely infected individuals will result in lower levels of proviral DNA and latent infectious virus at 48 weeks compared to acute infected individuals treated with LPV/r alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trizivir

Condition Name

Condition Name for Trizivir
Intervention Trials
HIV Infections 12
HIV Infection 4
HIV 3
HIV Associated Lipodystrophy Syndrome. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Trizivir
Intervention Trials
HIV Infections 16
Acquired Immunodeficiency Syndrome 5
Infections 5
Infection 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Trizivir

Trials by Country

Trials by Country for Trizivir
Location Trials
United States 105
Spain 8
Mexico 6
Canada 5
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Trizivir
Location Trials
New York 8
California 7
Georgia 6
Florida 6
Texas 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Trizivir

Clinical Trial Phase

Clinical Trial Phase for Trizivir
Clinical Trial Phase Trials
Phase 4 11
Phase 3 5
Phase 2/Phase 3 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Trizivir
Clinical Trial Phase Trials
Completed 16
Terminated 2
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Trizivir

Sponsor Name

Sponsor Name for Trizivir
Sponsor Trials
GlaxoSmithKline 7
National Institute of Allergy and Infectious Diseases (NIAID) 3
Gilead Sciences 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Trizivir
Sponsor Trials
Other 22
Industry 14
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Medtronic
Johnson and Johnson
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.